Sepracor

S. MAMEDE DO CORONADO, Portugal - Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term(1).